Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials

Objective: To evaluate the safety of daily oral ospemifene 60 mg, estrogen agonist/antagonist, used to treat moderate-to-severe dyspareunia due to postmenopausal vulvovaginal atrophy, which is part of genitourinary syndrome of menopause. Methods: Post hoc analysis of safety data (treatment-emergent...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Womens Health (Larchmt)
Hlavní autoři: Simon, James A., Altomare, Corrado, Cort, Susannah, Jiang, Wei, Pinkerton, JoAnn V.
Médium: Artigo
Jazyk:Inglês
Vydáno: Mary Ann Liebert, Inc. 2018
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5771532/
https://ncbi.nlm.nih.gov/pubmed/29064335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/jwh.2017.6385
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky